About Us
CRISPRomics®
+
CRISPRomics®
Publications
Pipeline
+
Pipeline®
Expanded Access Policy
News
People
+
Leadership Team
Board of Directors
Careers
Contact
Follow us on Twitter
Find us on LinkedIn
AACR 2023 Parpi combination
April 17, 2023
“KSQ-4279, a first-in-class USP1 inhibitor, shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers”
© 2023 KSQ Therapeutics, Inc. All rights reserved.